This site is intended for healthcare professionals
Anti-TNF biosimilars for rheumatic diseases: the key to early treatment?

Anti-TNF biosimilars webinars

Read time: 90 mins
Last updated:17th Nov 2022
Published:5th May 2022

Would you like to learn more about how anti-TNF biosimilars fit into management of rheumatoid arthritis? Join Professor Peter C Taylor in our webinar series to discover:

  • Key clinical evidence for safety and efficacy of anti-TNF biosimilars in rheumatoid arthritis and axial spondylarthritis
  • Expert discussion on how anti-TNF biosimilars can address unmet needs in rheumatoid arthritis, including early treatment access
  • Tips for switching to biosimilars in practice

Anti-TNF biosimilars in rheumatoid arthritis - evidence for place in therapy

Chaired by Professor Peter C. Taylor from Oxford University (UK) and joined by guest faculty Professor Christopher Edwards from University Hospital Southampton NHS Foundation Trust (UK) this webinar explores the clinical evidence behind anti-TNF biosimilars in rheumatoid arthritis (RA), how anti-TNF biosimilars can help to address unmet needs, and how they fit into management.

Watch the webinar

Watch the full 30-minute webinar on ‘Anti-TNF biosimilars in rheumatoid arthritis – evidence for place in therapy’ which took place 28 April 2022 to hear in-depth discussion about the clinical evidence, potential for early treatment and the audience Q&A on how biosimilars fit into the RA treatment landscape.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Integrating anti-TNF biosimilars into management of rheumatoid arthritis: when and how?

Join Professor Peter C. Taylor from Oxford University (UK) and joined by guest faculty Professor Josef Smolen from the Medical University of Vienna in this webinar that explores the concept of biosimilar, the capacity of these products to reduce the cost of the RA treatment, how their efficacy compares with their originators and their implementation in the EULAR guideline recommendations.

Watch the webinar

Watch the full 30-minute webinar on ‘Integrating anti-TNF biosimilars into management of rheumatoid arthritis: when and how?’ which took place 1 September 2022 to hear in-depth discussion about the biosimilars in the context of RA treatment, new guidelines and the audience Q&A on how biosimilars fit into the RA treatment landscape.

Video chapters

  1. Introduction and agenda (0:00)
  2. Current perspectives on biosimilars (1:35)
  3. Q&A: Do the clinical differences in the originator batches or the biosimilars result in any clinical differences? (XXX)
  4. Q&A: Is there an advantage in looking at the device that administers the drug? (XXX)
  5. Q&A: How many different anti-TNF agents would you try before switching to another mechanism of action? (XXX)
  6. Q&A: Switch to a biosimilar from an originator when the patient has the disease controlled with the originator? (XXX)
  7. Q&A: How can we prevent deformities in advanced cases of rheumatoid arthritis? (XXX)
  8. Q&A: What is the biggest benefit of anti-TNFs in rheumatic diseases in adults and is the benefits for children or adolescents somehow different? (XXX)
  9. Closing remarks and thank you (XXX)

Watch the highlights

Short on time? Catch up on the highlights from the webinar and Q&A session.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Chaired by Professor Peter C. Taylor from Oxford University (UK) and joined by guest faculty Professor Xenofon Baraliakos from Ruhr-University Bochum (Germany) this webinar explores the clinical evidence behind anti-TNF biosimilars in spondyloarthritis, guidelines and advice for switching to a biosimilar and how they fit into clinical management.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Meet the experts

Professor Peter Taylor.pngProfessor Peter C. Taylor

Professor Taylor is the Director of Clinical Sciences, Botnar Research Centre, University of Oxford, United Kingdom. He has over thirty years of experience in clinical trial design and international leadership in studies of biologic and small molecular therapies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, including the earliest seminal trials of anti-TNF and anti-IL-6 receptor therapy. Professor Taylor has specialist clinical interests in novel therapies, rheumatoid and early arthritis.

Disclosures: Professor Taylor has declared research grants from Celgene and Galapagos, and consultation fees from AbbVie, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Nordic Pharma, Novartis, Pfizer, Roche, Sanofi and UCB.

 

Professor Christopher Edwards.jpgProfessor Christopher Edwards

Professor Edwards is Co-Director of the NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, United Kingdom. He is Clinical Director of the Southampton Musculoskeletal Research Unit, a recognised EULAR centre of excellence, and is the Chair of the EULAR Education Committee. As Co-Director of the NIHR Southampton Clinical Research Facility, he is engaged with running a large translational research facility with first-in-human and phase 1 experience. He has been an Investigator on a number of clinical trials of therapies for inflammatory rheumatic diseases and more recently has worked on COVID vaccine (Oxford/Astra-Zeneca studies and COVBOOST) and therapeutic studies (AGILE Platform).  

Disclosures: Professor Edwards has declared receiving fees from AbbVie, Biogen, Bristol Myers Squibb, Celgene, Eli Lilly, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, Sanofi, for the following activities: advisory boards, speaker’s bureau, and research support.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: